Применение каннабиноидов в терапии психических и поведенческих расстройств
Рекомендуемое оформление библиографической ссылки:
Клименко Т.В., Корчагина Г.А., Игумнов С.А. Применение каннабиноидов в терапии психических и поведенческих расстройств // Российский психиатрический журнал. 2021. №2. С. 62-72.
В научном обзоре с целью исследования актуального состояния вопроса по использованию каннабиноидов в медицинских целях был проведён анализ доступных зарубежных систематических обзоров и рандомизированных контролируемых исследований по изучению эффективности и безопасности лекарственных препаратов на основе каннабиса у пациентов с различными, в том числе психическими, расстройствами. Показано, что накопленные к настоящему времени сведения об эффективности использования каннабиса и его метаболитов в медицинской практике противоречивы, не дают однозначного мнения по его терапевтической эффективности, что требует дальнейшего изучения терапевтического потенциала каннабиноидов с оценкой долгосрочных эффектов у максимально большого количества пациентов.
Ключевые слова каннабис; каннабиноидные рецепторы; психические расстройства; лечение; терапевтическая эффективность
1. Russo EB, Guy GW, Robson PJ. Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers. 2007;4(8):1729–43. DOI: https://doi.org/10.1002/cbdv.200790150 2. IOM (Institute of Medicine). Marijuana and medicine: Assessing the science base. Washington, DC: National Academy Press; 1999. 288 p. DOI: https://doi.org/10.17226/6376 3. Grotenhermen F, Muller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int. 2012;109(29–30):495–501. DOI: https://doi.org/10.3238/arztebl.2012.0495 4. NCSL (National Conference of State Legislatures). State medical marijuana laws. URL: http:// www.ncsl.org/research/health/state-medical-marijuana-laws.aspx (accessed on: 24.03.2021). 5. Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: Pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci. 20212;367(1607):3353–63. DOI: https://doi.org/10.1098/rstb.2011.0381 6. Schauer GL, King BA, Bunnell RE, et al. Toking, vaping, and eating for health or fun: Marijuana use patterns in adults, U.S., 2014. Am J Prev Med. 2016;50(1):1–8. DOI: https://doi.org/10.1016/j.amepre.2015.05.027 7. GW Pharmaceuticals. Prescriber information. November 15, 2016. URL: http://dev-gwpharma.pantheonsite.io/products-pipeline/sativex/prescriber-information-full (accessed on: 24.03.2021). 8. Belendiuk KA, Baldini LL, Bonn-Miller MO. Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders. Addict Sci Clin Pract. 2015;10:10. DOI: https://doi.org/10.1186/s13722-015-0032-7 9. Allsop DJ, Copeland J, Lintzeris N, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: A randomized clinical trial. JAMA Psychiatry. 2014;71(3):281–91. DOI: https://doi.org/10.1001/jamapsychiatry.2013.3947 10. Romancova TI. Jendokannabinoidnaja sistema: struktura i potencial'nye vozmozhnosti v reguljacii massy tela. Ozhirenie i metabolizm. 2006;(2):2–11. (In Russ.) 11. Ovsjannikov VG, et al. Antinociceptivnaja Sistema. Medicinskij vestnik Juga Rossii. 2014;(3):46–54. (In Russ.) DOI: https://doi.org/10.21886/2219-8075-2014-3-46-54 12. APA (American Psychiatric Association). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing; 2013. 991 p. 13. Nezhuta AJu, Melik-Kasumov TB, Ivanova EV. Vlijanie ligandov kannabinoidnyh receptorov na latentnyj period bolevogo refleksa i afferentnuju impul'saciju v podkozhnom nerve bedra zdorovyh krys. Zhurnal Grodnenskogo gosudarstvennogo medicinskogo universiteta. 2009;2(26):46–8. (In Russ.) 14. Churjukanov VV, Hodorovich NA, Shevelev OA. Agonisty kannabinoidnyh receptorov usilivajut kortikal'nyj kontrol' nociceptivnyh signalov v jadrah trojnichnogo nerva. Bolevye sindromy v medicinskoj praktike: Materialy XVII Ros. nauch.-prakt. konf. s mezhdunar. Uchastiem. Rossijskij zhurnal boli. 2011;(2):20. (In Russ.) 15. Krylatov AV. Kannabinoidergicheskaja reguljacija funkcional'nogo sostojanija serdca. Rol' vegetativnoj nervnoj sistemy. Rossijskij fiziologicheskij zhurnal im. IM Sechenova. 2017;103(7):727–43. (In Russ.) 16. Tromza VE, Nikiforova IN. Anal'geticheskie svojstva kannabinoidnyh ligandov WIN 55,212–2 i AM 1241 v testah otdergivanija hvosta i gorjachej plastiny. Rossijskij zhurnal boli. 2010;1(26):8–11. (In Russ.) 17. Molchanova AJu, Ulashhik VS. Kannabinoidy i molekuljarno-biologicheskie mehanizmy kancerogeneza. Zdravoohranenie (Minsk). 2015;(2):32–40. (In Russ.) 18. NIH (National Institutes of Health). The dementias: Hope through research. NIH Publication No. 17-NS-2252. December 2017. URL: https://order.nia.nih.gov/sites/default/files/2018-01/the-dementias-hope-through-research.pdf (accessed on: 24.03.2021). 19. NIA (National Institute on Aging). n.d. About Alzheimer's disease: Other dementias. URL: https://www.nia.nih.gov/alzheimers/topics/other-dementias (accessed оn: 24.03.2021). 20. Krishnan S, Cairns R, Howard R. Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev. 2009;(2):CD007204. DOI: https://doi.org/10.1002/14651858.CD007204.pub2 21. Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet Neurol. 2003;2(5):291–8. DOI: https://doi.org/10.1016/s1474-4422(03)00381-8 22. Grundy RI. The therapeutic potential of the cannabinoids in neuroprotection. Expert Opin Investig Drugs. 2002;11(10):1365–74. DOI: https://doi.org/10.1517/13543784.11.10.1365 23. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and delta- 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA. 1998;95(14):8268–73. DOI: https://doi.org/10.1073/pnas.95.14.8268 24. Shen M, Thayer SA. Cannabinoid receptor agonists protect cultured rat hip-pocampal neurons from excitotoxicity. Mol Pharmacol. 1998;54(3):459–62. DOI: https://doi.org/10.1124/mol.54.3.459 25. Volicer L, Stelly M, Morris J, et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 1997;12(9):913–9. PMID: 9309469 26. van den Elsen GAH, Ahmed AIA, Verkes RJ, et al. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial. Neurology. 2015;84(23):2338–46. DOI: https://doi.org/10.1212/WNL.0000000000001675 27. Gardner EL. Endocannabinoid signaling system and brain reward: Emphasis on dopamine. Pharmacol Biochem Behav. 2005;81(2):263–84. DOI: https://doi.org/10.1016/j.pbb.2005.01.032 28. Heifets BD, Castillo PE. Endocannabinoid signaling and long-term synaptic plasticity. Annu Rev Physiol. 2009;71:283–306. DOI: https://doi.org/10.1146/annurev.physiol.010908.163149 29. Budney AJ, Vandrey RG, Hughes JR, et al. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend. 2007;86(1):22–9. DOI: https://doi.org/10.1016/j.drugalcdep.2006.04.014 30. Haney M, Hart CL, Vosburg SK, et al. Marijuana withdrawal in humans: Effects of oral THC or divalproex. Neuropsychopharmacology. 2004;29(1):158–70. DOI: https://doi.org/10.1038/sj.npp.1300310 31. Levin FR, Mariani JJ, Brooks DJ, et al. Dronabinol for the treatment of cannabis dependence: A randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2011;116(1–3):142–50. DOI: https://doi.org/10.1016/j.drugalcdep.2010.12.010 32. Marshall K, Gowing L, Ali R, Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev. 2014;12(12):CD008940. DOI: https://doi.org/10.1002/14651858.CD008940.pub2 33. Morgan CJA, Das RK, Joye A, et al. Cannabidiol reduces cigarette consumption in tobacco smokers: Preliminary findings. Addict Behav. 2013;38(9):2433–6. DOI: https://doi.org/10.1016/j.addbeh.2013.03.011 34. NIMH (National Institute of Mental Health). Schizophrenia. 2015. URL: https://www.nimh.nih.gov/health/publications/schizophrenia-booklet-12-2015/index.shtml (accessed on: 24.03.2021). 35. McLoughlin BC, Pushpa-Rajah JA, Gillies D, et al. Cannabis and schizophrenia. Cochrane Database Syst Rev. 2014;(10):CD004837. DOI: https://doi.org/10.1002/14651858.CD004837.pub3 36. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA. 2015;313(24):2456247. DOI: https://doi.org/10.1001/jama.2015.6358 37. ADAA (Anxiety and Depression Association of America). Depression. 2016. URL: https://www.adaa.org/understanding-anxiety/depression (accessed on: 24.03.2021). 38. NIDA (National Institute on Drug Abuse). Research reports: Marijuana. 2015. URL: https://www.drugabuse.gov/sites/default/files/mjrrs_4_15.pdf (accessed on: 24.03.2021). 39. Jetly R, Heber A, Fraser G, Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015;51:585–8. DOI: https://doi.org/10.1016/j.psyneuen.2014.11.002 40. Sateia MJ. International classification of sleep disorders, third edition: Highlights and modifications. Chest. 2014;146(5):1387–94. DOI: https://doi.org/10.1378/chest.14-0970 41. Garcia AN, Salloum IM. Polysomnograhic sleep disturbances in nicotine, cafeine, alcohol, cocaine, opioid, and cannabis use: A focused review. Am J Addict. 2015;24(7):590–8. DOI: https://doi.org/10.1111/ajad.12291 42. Andries A, Frystyk J, Flyvbjerg A, Støving RK. Dronabinol in severe, persistent anorexia nervosa: a randomized controlled trial. Int J Eat Disord. 2014;47:18–23. 43. Cyr C, Arboleda MF, Aggarwal SK, et al. Cannabis in palliative care: current challenges and practical recommendations. Ann Palliat Med. 2018;7(4):463–77. DOI: https://doi.org/10.21037/apm.2018.06.04 44. Allan GM, Finley CR, Ton J, et al. Systematic review of systematic reviews for medical cannabinoids. Pain, nausea and vomiting, spasticity, and harms. Can Fam Physician. 2018;64(2):e78–e94. PMID: 29449262 45. Rasche T, Emmert D, Stieber C, et al. Cannabis und Cannabinoide – erleichterter Zugang, Hype und Enttäuschung: Was ist gesichert in der Therapie? [Cannabis and cannabinoids-easier access, hype and disappointment: What has been confirmed in therapy?]. Internist (Berl). 2019;60(3):309–14. (In German) DOI: https://doi.org/10.1007/s00108-019-0556-0 46. Briscoe J, Kamal AH, Casarett DJ. Top Ten Tips Palliative Care Clinicians Should Know About Medical Cannabis. J Palliat Med. 2019;22(3):319–25. DOI: https://doi.org/10.1089/jpm.2018.0641 47. Ispol'zovanie kannabisa i kannabinoidov v medicinskih, nauchnyh i “rekreacionnyh” celjah: riski i pol'za. Tematicheskaja glava godovogo doklada Mezhdunarodnogo komiteta po kontrolju nad narkotikami OON (MKKN) za 2018 g. Voprosy narkologii. 2019;2(173):59–80. (In Russ.)
DOI: http://dx.doi.org/10.47877/1560-957Х-2021-10207
Метрики статей
Metrics powered by PLOS ALM